Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
INGELHEIM, Germany & INDIANAPOLIS -- (BUSINESS WIRE) -- Empagliflozin reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and......
